查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1930136

全球坐骨神經痛治療市場：市場規模、佔有率、成長率、產業分析、依類型、應用和地區劃分的分析以及未來預測（2026-2034）

Sciatica Treatment Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 110 Pages | 商品交期: 請詢問到貨日

價格

坐骨神經痛治療市場成長因素

預計2025年全球坐骨神經痛治療市場規模將達59.2億美元，從2026年的65.2億美元成長至2034年的144.2億美元，預測期內複合年增長率高達10.44%。北美將在2025年以46.1%的市場佔有率引領市場，這主要得益於人們對慢性腰痛的高度關注、處方量的增長以及大型製藥公司的存在。

坐骨神經痛（也稱為腰椎神經根性疼痛）的特徵是由於坐骨神經受壓或受刺激而引起的疼痛從腰部放射至腿部。椎間盤突出、椎管狹窄和腰椎神經根病變的發生率不斷上升，推動了全球對有效藥物和介入治療的需求。

市場驅動因素

市場成長的主要驅動因素是全球坐骨神經痛盛行率的上升。年盛行率介於1.0%至5.0%之間，終生盛行率介於13%至40%之間。非處方藥和處方藥（包括非類固醇抗發炎藥 (NSAIDs)、皮質類固醇、抗憂鬱藥和鴉片類藥物）的日益普及，顯著推動了治療方案的採用。

人們對硬膜外類固醇注射和疼痛管理療法等先進療法的認識不斷提高，以及市場參與者臨床試驗活動的增加，進一步推動了市場擴張。此外，缺乏獲得 FDA 批准的長期治療方案也促使企業投資於創新藥物研發計畫。

新冠疫情的影響

2020 年，由於就診量減少以及藥品生產和供應鏈中斷，新冠疫情對坐骨神經痛治療市場產生了負面影響。由於醫療系統優先治療新冠患者，處方量下降。

然而，隨著疫情後的復甦，慢性病患者的就診量已恢復。到 2021 年，隨著限制措施的放鬆，對坐骨神經痛治療的需求增加，製藥公司在醫院和零售藥局的處方藥銷售額也隨之增長。

市場趨勢

影響市場發展的關鍵趨勢之一是醫療機構和研究機構所進行的宣傳教育活動日益增加。大眾對坐骨神經痛的症狀、風險因素和治療方案的了解不斷加深，從而提高了早期診斷和治療率。

國家和地區層級針對慢性下背痛管理和推廣非鴉片類鎮痛療法的措施正在影響處方模式。微創手術和非鴉片類藥物在醫療機構的普及進一步推動了市場成長。

限制因子

儘管市場成長前景強勁，但長期治療坐骨神經痛的副作用和併發症正在限制市場發展。長期使用皮質類固醇、鴉片類藥物和侵入性治療可能導致嚴重的併發症，從而限制了這些療法的普及。

此外，坐骨神經痛的治療會帶來沉重的經濟負擔，因為其直接和間接的醫療成本都很高。現有療法的長期療效有限，以及對感染和全身性副作用等併發症的擔憂，可能會限制市場成長。

市場區隔分析

依類型劃分：

預計到2026年，慢性坐骨神經痛市場將佔主導地位，市場佔有率高達71.47%，這主要得益於持續性疼痛的高發生率以及硬膜外注射和阿片類藥物療法的日益普及。急性坐骨神經痛市場預計將穩定成長，這得益於人們對該疾病的認識不斷提高以及早期治療的推廣。

依藥物類別劃分：

到2026年，非類固醇抗發炎藥物 (NSAID) 市場佔有率將達到44.17%，這主要得益於其廣泛的可及性、價格優勢以及處方頻率。由於硬膜外類固醇注射的需求不斷增長，預計皮質類固醇的增長速度最快。

依分銷管道劃分：

到2026年，零售和線上藥局通路將佔市場主導地位，市佔率達到80.52%，這主要得益於較高的自付費用以及疼痛管理藥物的便捷取得。由於住院患者數量的增加，預計醫院藥房也將保持穩定成長。

區域因素

  • 北美：預計到2025年，北美市場規模將達到27.3億美元，主要得益於較高的處方率和較高的藥物認知度。 預計到2026年，美國市場規模將達到29.3億美元。 歐洲：由於疾病高發生率和系統化的疼痛管理指南，市場預計將保持溫和成長。 亞太地區：由於背痛發病率上升和政府舉措，預計市場將具有強勁的成長潛力。預計到2026年，日本市場規模將達到2.8億美元，中國將達到2.4億美元，印度將達到1.7億美元。 拉丁美洲、中東和非洲：由於疼痛管理療法的普及，預計市場將保持穩定成長。

目錄

第一章：引言

第二章：摘要整理

第三章：市場動態

  • 市場驅動因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢

第四章：關鍵考慮因素

  • 主要國家/地區坐骨神經痛盛行率（2025 年）
  • 主要公司近期產品發布
  • 關鍵產業趨勢：併購、業務合作
  • 新冠疫情對全球市場的影響

第五章 全球坐骨神經痛治療市場分析：洞察與預測（2021-2034）

  • 市場分析、洞察與預測：依類型劃分
    • 急性
    • 慢性
  • 市場分析、洞察與預測：依藥物類別劃分
    • 非類固醇抗發炎藥 (NSAIDs)
    • 皮質類固醇
    • 抗憂鬱藥
    • 其他
  • 市場分析、洞察與預測：依通路劃分
    • 醫院藥房
    • 零售和線上藥房
  • 市場分析、洞察與預測：依地區劃分
    • 北美
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第六章 北美坐骨神經痛治療市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 美國
    • 加拿大

第七章：歐洲坐骨神經痛治療市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 義大利
    • 其他歐洲國家

第八章：亞太地區坐骨神經痛治療市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 日本
    • 中國
    • 印度
    • 澳大利亞
    • 東南亞亞洲
    • 亞太其他地區

第九章：拉丁美洲坐骨神經痛治療市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地區

第十章：中東與非洲坐骨神經痛治療市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 海灣合作委員會（GCC）國家
    • 南非
    • 中東和非洲其他地區

第11章 競爭分析

  • 世界市場佔有率分析(2025年)
  • 企業簡介
    • Pfizer Inc.
    • Abbott
    • Bayer AG
    • Endo International plc.
    • Johnson & Johnson Services, Inc.
    • GSK plc.
    • Novartis AG
    • Bristol Myers Squibb
    • Amneal Pharmaceuticals LLC.
    • Sorrento Therapeutics
Product Code: FBI108950

Growth Factors of sciatica treatment Market

The global sciatica treatment market was valued at USD 5.92 billion in 2025 and is projected to grow from USD 6.52 billion in 2026 to USD 14.42 billion by 2034, registering a strong CAGR of 10.44% during the forecast period. North America dominated the market with a 46.1% share in 2025, supported by high awareness of chronic lower back pain, increased prescription volumes, and the presence of leading pharmaceutical companies.

Sciatica, also known as lumbar radicular pain, is characterized by pain radiating from the lower back to the legs due to compression or irritation of the sciatic nerve. The rising incidence of herniated discs, spinal stenosis, and lumbar radiculopathy is driving demand for effective pharmacological and interventional treatment options worldwide.

Market Drivers

A key driver of market growth is the increasing prevalence of sciatica globally, with annual incidence rates ranging from 1.0% to 5.0% and lifetime prevalence between 13% and 40%. The growing use of over-the-counter and prescription drugs, including NSAIDs, corticosteroids, antidepressants, and opioids, has significantly contributed to treatment adoption.

Rising awareness of advanced treatment modalities such as epidural steroid injections and analgesic therapies, along with increased clinical trial activity by market players, is further accelerating market expansion. Additionally, the lack of long-term FDA-approved therapies has encouraged companies to invest in innovative drug development programs.

COVID-19 Impact

The COVID-19 pandemic negatively affected the sciatica treatment market in 2020 due to reduced hospital visits and disruptions in pharmaceutical manufacturing and supply chains. Prescription volumes declined as healthcare systems prioritized COVID-19 care.

However, post-pandemic recovery led to a rebound in patient visits for chronic conditions. By 2021, the relaxation of restrictions resulted in increased demand for sciatica treatments, with pharmaceutical companies witnessing growth in prescription drug sales across hospitals and retail pharmacies.

Market Trends

One of the major trends shaping the market is the rise in awareness programs initiated by healthcare authorities and research institutions. Increased public knowledge about sciatica symptoms, risk factors, and treatment options has improved early diagnosis and treatment uptake.

National and regional initiatives focusing on chronic lower back pain management and the promotion of non-opioid pain therapies are influencing prescribing patterns. The growing availability of minimally invasive procedures and non-opioid medications across healthcare settings is further strengthening market growth.

Restraining Factors

Despite strong growth prospects, the market faces restraints due to side effects and complications associated with long-term sciatica treatments. Chronic use of corticosteroids, opioids, and invasive procedures can lead to significant morbidity, limiting their adoption.

Additionally, sciatica treatment imposes a substantial economic burden due to high direct and indirect healthcare costs. Limited long-term efficacy of existing therapies and concerns regarding complications such as infections and systemic side effects may restrict market growth.

Segmentation Analysis

By Type:

The chronic sciatica segment dominated the market with a 71.47% share in 2026, driven by the high prevalence of long-lasting pain and increased use of epidural injections and opioid therapies. The acute segment is expected to grow steadily due to rising awareness and early treatment adoption.

By Drug Class:

The NSAIDs segment accounted for 44.17% of the market in 2026, supported by widespread availability, affordability, and frequent prescriptions. Corticosteroids are anticipated to witness the fastest growth due to rising demand for epidural steroid injections.

By Distribution Channel:

The retail and online pharmacies segment dominated with an 80.52% share in 2026, driven by high out-of-pocket spending and easy access to pain management medications. Hospital pharmacies are expected to grow steadily due to increasing patient admissions.

Regional Insights

  • North America: Valued at USD 2.73 billion in 2025, driven by high prescription rates and awareness. The U.S. market is projected to reach USD 2.93 billion by 2026.
  • Europe: Moderate growth supported by high disease prevalence and structured pain management guidelines.
  • Asia Pacific: Strong growth potential due to rising lower back pain incidence and government initiatives. By 2026, Japan is projected to reach USD 0.28 billion, China USD 0.24 billion, and India USD 0.17 billion.
  • Latin America & Middle East & Africa: Expected to grow steadily due to expanding access to pain management therapies.

Competitive Landscape

Key players include Pfizer Inc., Abbott, Bayer AG, Johnson & Johnson, Novartis AG, GSK plc., and Sorrento Therapeutics. These companies focus on portfolio expansion, clinical trials, and strategic collaborations to strengthen their market presence.

Conclusion

The global sciatica treatment market is set to witness robust growth from 2025 to 2034, driven by rising disease prevalence, increasing awareness, and growing demand for effective pain management solutions. While concerns regarding side effects and long-term efficacy remain, ongoing clinical research, new drug development, and supportive healthcare initiatives are expected to sustain market momentum. By 2034, the market is projected to reach USD 14.42 billion, reflecting the expanding need for advanced and safer sciatica treatment options worldwide.

Segmentation By Type

  • Acute
  • Chronic

By Drug Class

  • Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
  • Corticosteroids
  • Antidepressants
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail & Online Pharmacies

By Region

  • North America (By Type, Drug Class, Distribution Channel, and Country)
    • U.S.
    • Canada
  • Europe (By Type, Drug Class, Distribution Channel, and Country/Sub-Region)
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific (By Type, Drug Class, Distribution Channel, and Country/Sub-Region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Type, Drug Class, Distribution Channel, and Country/Sub-Region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Type, Drug Class, Distribution Channel, and Country/Sub-Region)
    • GCC
    • South Africa
    • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Sciatica, By Key Countries, 2025
  • 4.2. Recent Product Launches, By Key Players
  • 4.3. Key Industry Developments - Mergers, Acquisitions, and Partnerships
  • 4.4. Impact of COVID-19 on the Global Market

5. Global Sciatica Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Type
    • 5.1.1. Acute
    • 5.1.2. Chronic
  • 5.2. Market Analysis, Insights and Forecast - By Drug Class
    • 5.2.1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
    • 5.2.2. Corticosteroids
    • 5.2.3. Antidepressants
    • 5.2.4. Others
  • 5.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.3.1. Hospital Pharmacies
    • 5.3.2. Retail & Online Pharmacies
  • 5.4. Market Analysis, Insights and Forecast - By Region
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Latin America
    • 5.4.5. Middle East and Africa

6. North America Sciatica Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Type
    • 6.1.1. Acute
    • 6.1.2. Chronic
  • 6.2. Market Analysis, Insights and Forecast - By Drug Class
    • 6.2.1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
    • 6.2.2. Corticosteroids
    • 6.2.3. Antidepressants
    • 6.2.4. Others
  • 6.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.3.1. Hospital Pharmacies
    • 6.3.2. Retail & Online Pharmacies
  • 6.4. Market Analysis, Insights and Forecast - By Country
    • 6.4.1. U.S.
    • 6.4.2. Canada

7. Europe Sciatica Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Type
    • 7.1.1. Acute
    • 7.1.2. Chronic
  • 7.2. Market Analysis, Insights and Forecast - By Drug Class
    • 7.2.1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
    • 7.2.2. Corticosteroids
    • 7.2.3. Antidepressants
    • 7.2.4. Others
  • 7.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.3.1. Hospital Pharmacies
    • 7.3.2. Retail & Online Pharmacies
  • 7.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 7.4.1. U.K.
    • 7.4.2. Germany
    • 7.4.3. France
    • 7.4.4. Spain
    • 7.4.5. Italy
    • 7.4.6. Rest of Europe

8. Asia Pacific Sciatica Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Type
    • 8.1.1. Acute
    • 8.1.2. Chronic
  • 8.2. Market Analysis, Insights and Forecast - By Drug Class
    • 8.2.1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
    • 8.2.2. Corticosteroids
    • 8.2.3. Antidepressants
    • 8.2.4. Others
  • 8.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.3.1. Hospital Pharmacies
    • 8.3.2. Retail & Online Pharmacies
  • 8.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 8.4.1. Japan
    • 8.4.2. China
    • 8.4.3. India
    • 8.4.4. Australia
    • 8.4.5. Southeast Asia
    • 8.4.6. Rest of Asia Pacific

9. Latin America Sciatica Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Type
    • 9.1.1. Acute
    • 9.1.2. Chronic
  • 9.2. Market Analysis, Insights and Forecast - By Drug Class
    • 9.2.1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
    • 9.2.2. Corticosteroids
    • 9.2.3. Antidepressants
    • 9.2.4. Others
  • 9.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.3.1. Hospital Pharmacies
    • 9.3.2. Retail & Online Pharmacies
  • 9.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 9.4.1. Brazil
    • 9.4.2. Mexico
    • 9.4.3. Rest of Latin America

10. Middle East & Africa Sciatica Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Type
    • 10.1.1. Acute
    • 10.1.2. Chronic
  • 10.2. Market Analysis, Insights and Forecast - By Drug Class
    • 10.2.1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
    • 10.2.2. Corticosteroids
    • 10.2.3. Antidepressants
    • 10.2.4. Others
  • 10.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.3.1. Hospital Pharmacies
    • 10.3.2. Retail & Online Pharmacies
  • 10.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 10.4.1. GCC
    • 10.4.2. South Africa
    • 10.4.3. Rest of MEA

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. Pfizer Inc.
      • 11.2.1.1. Overview
      • 11.2.1.2. Products
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. financials (Based on Availability)
    • 11.2.2. Abbott
      • 11.2.2.1. Overview
      • 11.2.2.2. Products
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. financials (Based on Availability)
    • 11.2.3. Bayer AG
      • 11.2.3.1. Overview
      • 11.2.3.2. Products
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. financials (Based on Availability)
    • 11.2.4. Endo International plc.
      • 11.2.4.1. Overview
      • 11.2.4.2. Products
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. financials (Based on Availability)
    • 11.2.5. Johnson & Johnson Services, Inc.
      • 11.2.5.1. Overview
      • 11.2.5.2. Products
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. financials (Based on Availability)
    • 11.2.6. GSK plc.
      • 11.2.6.1. Overview
      • 11.2.6.2. Products
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. financials (Based on Availability)
    • 11.2.7. Novartis AG
      • 11.2.7.1. Overview
      • 11.2.7.2. Products
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. financials (Based on Availability)
    • 11.2.8. Bristol Myers Squibb
      • 11.2.8.1. Overview
      • 11.2.8.2. Products
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. financials (Based on Availability)
    • 11.2.9. Amneal Pharmaceuticals LLC.
      • 11.2.9.1. Overview
      • 11.2.9.2. Products
      • 11.2.9.3. SWOT Analysis
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. financials (Based on Availability)
    • 11.2.10. Sorrento Therapeutics
      • 11.2.10.1. Overview
      • 11.2.10.2. Products
      • 11.2.10.3. SWOT Analysis
      • 11.2.10.4. Recent Developments
      • 11.2.10.5. Strategies
      • 11.2.10.6. financials (Based on Availability)

List of Tables

  • Table 1: Global Sciatica Treatment Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 2: Global Sciatica Treatment Market Revenue (USD billion) Forecast, by By Drug Class, 2021-2034
  • Table 3: Global Sciatica Treatment Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 4: Global Sciatica Treatment Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 5: North America Sciatica Treatment Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 6: North America Sciatica Treatment Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 7: North America Sciatica Treatment Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 8: North America Sciatica Treatment Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 9: Europe Sciatica Treatment Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 10: Europe Sciatica Treatment Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 11: Europe Sciatica Treatment Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 12: Europe Sciatica Treatment Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 13: Asia Pacific Sciatica Treatment Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 14: Asia Pacific Sciatica Treatment Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 15: Asia Pacific Sciatica Treatment Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 16: Asia Pacific Sciatica Treatment Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 17: Latin America Sciatica Treatment Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 18: Latin America Sciatica Treatment Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 19: Latin America Sciatica Treatment Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 20: Latin America Sciatica Treatment Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 21: Middle East & Africa Sciatica Treatment Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 22: Middle East & Africa Sciatica Treatment Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 23: Middle East & Africa Sciatica Treatment Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 24: Middle East & Africa Sciatica Treatment Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Sciatica Treatment Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Sciatica Treatment Market Value Share (%), by Type, 2025 & 2034
  • Figure 3: Global Sciatica Treatment Market Value Share (%), by Drug Class, 2025 & 2034
  • Figure 4: Global Sciatica Treatment Market Value Share (%), by Distribution Channel, 2025 & 2034
  • Figure 5: Global Sciatica Treatment Market Value (USD billion), by Region, 2025 & 2034
  • Figure 6: North America Sciatica Treatment Market Value (USD billion), by Type, 2025 & 2034
  • Figure 7: North America Sciatica Treatment Market Value Share (%), by Type, 2025
  • Figure 8: North America Sciatica Treatment Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 9: North America Sciatica Treatment Market Value Share (%), by Drug Class, 2025
  • Figure 10: North America Sciatica Treatment Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 11: North America Sciatica Treatment Market Value Share (%), by Distribution Channel, 2025
  • Figure 12: North America Sciatica Treatment Market Value (USD billion), By Country, 2025 & 2034
  • Figure 13: North America Sciatica Treatment Market Value Share (%), By Country, 2025
  • Figure 14: Europe Sciatica Treatment Market Value (USD billion), by Type, 2025 & 2034
  • Figure 15: Europe Sciatica Treatment Market Value Share (%), by Type, 2025
  • Figure 16: Europe Sciatica Treatment Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 17: Europe Sciatica Treatment Market Value Share (%), by Drug Class, 2025
  • Figure 18: Europe Sciatica Treatment Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 19: Europe Sciatica Treatment Market Value Share (%), by Distribution Channel, 2025
  • Figure 20: Europe Sciatica Treatment Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 21: Europe Sciatica Treatment Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 22: Asia Pacific Sciatica Treatment Market Value (USD billion), by Type, 2025 & 2034
  • Figure 23: Asia Pacific Sciatica Treatment Market Value Share (%), by Type, 2025
  • Figure 24: Asia Pacific Sciatica Treatment Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 25: Asia Pacific Sciatica Treatment Market Value Share (%), by Drug Class, 2025
  • Figure 26: Asia Pacific Sciatica Treatment Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 27: Asia Pacific Sciatica Treatment Market Value Share (%), by Distribution Channel, 2025
  • Figure 28: Asia Pacific Sciatica Treatment Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 29: Asia Pacific Sciatica Treatment Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 30: Latin America Sciatica Treatment Market Value (USD billion), by Type, 2025 & 2034
  • Figure 31: Latin America Sciatica Treatment Market Value Share (%), by Type, 2025
  • Figure 32: Latin America Sciatica Treatment Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 33: Latin America Sciatica Treatment Market Value Share (%), by Drug Class, 2025
  • Figure 34: Latin America Sciatica Treatment Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 35: Latin America Sciatica Treatment Market Value Share (%), by Distribution Channel, 2025
  • Figure 36: Latin America Sciatica Treatment Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 37: Latin America Sciatica Treatment Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 38: Middle East & Africa Sciatica Treatment Market Value (USD billion), by Type, 2025 & 2034
  • Figure 39: Middle East & Africa Sciatica Treatment Market Value Share (%), by Type, 2025
  • Figure 40: Middle East & Africa Sciatica Treatment Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 41: Middle East & Africa Sciatica Treatment Market Value Share (%), by Drug Class, 2025
  • Figure 42: Middle East & Africa Sciatica Treatment Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 43: Middle East & Africa Sciatica Treatment Market Value Share (%), by Distribution Channel, 2025
  • Figure 44: Middle East & Africa Sciatica Treatment Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 45: Middle East & Africa Sciatica Treatment Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 46: Global Sciatica Treatment Market Share (%), By Company, 2025